Limited Competition for the Closeout of the SEARCH for Diabetes in Youth Cohort Study (R01 Clinical Trial Not Allowed) | RFA DK 19 507

Opportunity Information: Apply for RFA DK 19 507

The funding opportunity titled "Limited Competition for the Closeout of the SEARCH for Diabetes in Youth Cohort Study (R01 Clinical Trial Not Allowed)" (RFA-DK-19-507) is an NIH discretionary grant designed specifically to support the final phase, or closeout, of the long-running SEARCH for Diabetes in Youth Cohort Study. SEARCH is a major longitudinal research effort that assembled and followed a cohort of young people diagnosed with diabetes over time. Rather than funding new participant recruitment or launching new intervention work, this announcement is focused on completing the scientific work needed to fully analyze the cohort data and ensure the findings are properly shared with the broader research, clinical, and public health communities.

The core purpose of the FOA is to finalize analyses and disseminate results that describe how diabetes-related outcomes develop and change as affected youth age, with particular attention to the evolution of diabetes complications. This includes analyses related to mortality as well as the broader set of diabetes-associated complications that can emerge over the life course. In addition to clinical outcomes, the FOA emphasizes work on processes of care, meaning how healthcare is delivered and managed for these individuals, and on quality of life, recognizing that the lived experience and day-to-day impacts of diabetes are central endpoints alongside biomedical measures. In practical terms, applicants are expected to use the existing SEARCH cohort infrastructure and data resources to complete high-value analyses, publish and present results, and generally bring the study to a scientifically robust conclusion.

The mechanism is an R01 research project grant and it explicitly states "Clinical Trial Not Allowed," which signals that NIH does not intend to support prospective interventional clinical trials under this announcement. The supported activities are aligned with observational analyses, outcomes research, and dissemination based on already collected cohort data and follow-up. The funding activity category is listed under health (and food and nutrition/health), and the assistance listing (CFDA) number provided is 93.847, indicating it falls within the NIH portfolio associated with diabetes, endocrine, and metabolic disease research.

Eligibility is limited. The announcement indicates eligible applicants include public and state-controlled institutions of higher education, reflecting the targeted nature of the closeout funding and the expectation that established academic institutions involved in large cohort research are best positioned to complete the work. The FOA also clarifies boundaries around non-U.S. participation: non-domestic (non-U.S.) entities, meaning foreign institutions, are not eligible to apply as the applicant organization, and non-domestic components of U.S. organizations are not eligible to apply. At the same time, it allows "foreign components" as defined in the NIH Grants Policy Statement, which typically means that discrete elements of the project may involve foreign collaborations or activities when justified and compliant, even though the primary applicant must be a qualifying U.S. institution and the project cannot include non-domestic organizational components in the prohibited sense. Because NIH uses specific definitions for these terms, the announcement instructs applicants to consult the full funding announcement for detailed eligibility rules and how NIH will interpret foreign involvement.

Key administrative details include an original closing date of February 19, 2020, and an award ceiling of $1,700,000. The opportunity was created on November 8, 2019. The listing does not specify the number of expected awards in the provided excerpt, but the title "Limited Competition" suggests the applicant pool is restricted, often to existing awardees, designated institutions, or a defined set of participants in the original consortium, consistent with a closeout phase intended to finish and publish results rather than expand the study to new sites.

Overall, this FOA is best understood as targeted support to ensure the SEARCH cohort study yields its full scientific and public health value at the end of its funding lifecycle. It prioritizes rigorous final analyses on complications, mortality, care delivery, and quality of life in youth-onset diabetes, and it places strong emphasis on dissemination so that the knowledge gained can inform clinical practice, future research, and policy aimed at improving outcomes for young people living with diabetes.

• The National Institutes of Health in the food and nutrition, health sector is offering a public funding opportunity titled "Limited Competition for the Closeout of the SEARCH for Diabetes in Youth Cohort Study (R01 Clinical Trial Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.847.
• This funding opportunity was created on 2019-11-08.
• Applicants must submit their applications by 2020-02-19. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $1,700,000.00 in funding.
• Eligible applicants include: Public and State controlled institutions of higher education.

Apply for RFA DK 19 507

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: